Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care.
Company facts
| Company | Gilead Sciences, Inc. |
|---|---|
| Symbol | GILD |
| Exchange | XNAS |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Market cap | $179.56B (Massive market data, 2026-09-10) |
| Employees | 17,000 |
| Country | United States |
| Website | https://www.gilead.com |
Trading — Gilead Sciences, Inc.
| Last price | $143.72 |
|---|---|
| Change | -0.75% |
| Previous close | $144.81 |
| Day range | $143.50 – $145.99 |
| 50-day average | $136.60 |
| 200-day average | $134.36 |
| Average volume | 7,053,146 |
Price basis: 2026-09-11T20:59:28.859196+00:00
Valuation and financial health
| Earnings per share | $-2.61 |
|---|---|
| Price / book | 15.18 |
| Price / cash flow | 13.25 |
| Enterprise value / EBITDA | 62.77 |
| Enterprise value / sales | 6.65 |
| Debt / equity | 2.22 |
| Current ratio | 1.27 |
| Dividend yield | 2.27% |
| Free cash flow | $12.94B |
| Cash ratio | 0.29 |
| Enterprise value | $202.62B |
Reported 2026-09-10
Earnings
| Report date | 2026-10-29 |
|---|---|
| Session | After Hours |
| Fiscal quarter ending | Sep/2026 |
| EPS estimate | $2.15 |
| Year-ago EPS | $2.47 |
| Analyst estimates | 6 |
Source: Nasdaq.com public earnings calendar
Other Healthcare companies
Live data
Live quotes, options positioning, insider and congressional filings for GILD are on the IntelTrends dashboard.